747 related articles for article (PubMed ID: 28685934)
1. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
2. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Petrykiv SI; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2017 Oct; 19(10):1363-1370. PubMed ID: 28295959
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
5. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ
J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153
[TBL] [Abstract][Full Text] [Related]
6. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
7. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
[TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
[TBL] [Abstract][Full Text] [Related]
11. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
[TBL] [Abstract][Full Text] [Related]
12. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
[TBL] [Abstract][Full Text] [Related]
13. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
14. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Heerspink HJL; Sjöström CD; Inzucchi SE; Hallow MK; Cain VA; Rossing P; Stefansson BV; Sartipy P
Diabetes Obes Metab; 2019 Mar; 21(3):720-725. PubMed ID: 30414240
[TBL] [Abstract][Full Text] [Related]
15. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
[TBL] [Abstract][Full Text] [Related]
16. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
17. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
18. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
[TBL] [Abstract][Full Text] [Related]
20. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
